NCT05752552View on ClinicalTrials.gov

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Adult Solid TumorAdvanced Solid TumorRefractory TumorNon-small Cell Lung CancerNon-small Cell CarcinomaLung CancerHereditary Renal Papillary Cancer
Interventions
DRUG

DO-2

Deuterated MET kinase inhibitor

Trial Locations (8)

9000

Universitair Ziekenhuis Gent, Ghent

Unknown

Institut Roi Albert II - UC Louvain, Brussels

UZA, Edegem

Centre Georges-François Leclerc - CHU Dijon, Dijon

Institut Cœur Poumon - CHU Lille, Lille

Centre Léon Bérard, Lyon

Radboud UMC, Nijmegen

Erasmus Medical Centre, Rotterdam

Sponsors

Lead Sponsor

DeuterOncology
All Listed Sponsors
lead

DeuterOncology

INDUSTRY